Analysis of genetic heterogeneity in the HCAR adenovirus-binding Ig1 domain in a Caucasian Flemish population
Abstract Background Polymorphisms in the gene that encodes the human cellular receptor for group B coxsackieviruses and adenoviruses (HCAR) could be responsible for differences in susceptibility to infections with these pathogens. Moreover, adenovirus subgroup C-mediated gene therapy could be influenced by mutations in the coding exons for the aminoterminal immunoglobulin-like 1 (Ig1) domain, which is the essential component for adenovirus fiber knob binding. Results Using two primersets in the adjacent intron sequences, HCAR exons 2 and 3, which comprise the full-length Ig1 domain, were ampli... Mehr ...
Verfasser: | |
---|---|
Dokumenttyp: | Artikel |
Erscheinungsdatum: | 2002 |
Reihe/Periodikum: | BMC Genetics, Vol 3, Iss 1, p 1 (2002) |
Verlag/Hrsg.: |
BMC
|
Schlagwörter: | Genetics / QH426-470 |
Sprache: | Englisch |
Permalink: | https://search.fid-benelux.de/Record/base-29060470 |
Datenquelle: | BASE; Originalkatalog |
Powered By: | BASE |
Link(s) : | https://doi.org/10.1186/1471-2156-3-1 |
Abstract Background Polymorphisms in the gene that encodes the human cellular receptor for group B coxsackieviruses and adenoviruses (HCAR) could be responsible for differences in susceptibility to infections with these pathogens. Moreover, adenovirus subgroup C-mediated gene therapy could be influenced by mutations in the coding exons for the aminoterminal immunoglobulin-like 1 (Ig1) domain, which is the essential component for adenovirus fiber knob binding. Results Using two primersets in the adjacent intron sequences, HCAR exons 2 and 3, which comprise the full-length Ig1 domain, were amplified by polymerase chain reactions in 108 unselected and unrelated healthy Belgian volunteers. After nucleotide sequencing, no polymorphisms could be demonstrated in the adenovirus-binding Ig1 exons 2 and 3 of the HCAR gene. Conclusions The adenovirus-binding Ig1 domain seems to be a highly conserved region in the Caucasian population which is a reassuring finding regarding adenovector-based gene therapy.